Autobahn News

Autobahn Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference

Autobahn Therapeutics Strengthens its Team to Support its Continued Growth

Autobahn Therapeutics Completes Successful Pre-IND Meeting with FDA

Autobahn Therapeutics Appoints Business Leader, Scott Forrest, Ph.D., as Chief Business Officer

Sehr gut: Autobahn roars out of stealth mode with $76M, new leitmotif in MS

ARCH-backed Autobahn launches with $76M to rebuild myelin and reverse MS

Autobahn Therapeutics Launches with $76 Million Series B Financing to Develop Next Generation Therapies for CNS Disorders